The increased prevalence of hypophysitis in patients treated with anti-CTLA-4 has also been related to a possible ectopic expression of CTLA-4 at the pituitary level, which may act as an autoantigen evoking an autoimmune attack by anti-CTLA-4 antibodies when administered in cancer patients [6,28]. Here, CTLA4 is linked to hypophysitis.